SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now
EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Recent Searches

    The NFL pledges $1 million toward cannabis research

    By

    The National Football League and its players’ association announced they’re putting $1 million behind medical cannabis for pain research, reports the Chicago Sun-Times.



    No pain, big gain

    NFL chief medical officer Dr. Allen Sills said they want to better-understand if cannabis can effectively manage pain and do so safely on its own or combined with other medications.

    “Players are always looking to find treatments that are going to improve their quality of life,” he said. “But at the same time, players are significantly concerned about the impact on performance.”

    https://twitter.com/kylejaeger/status/1402355036810735621

    Slow but steady progress

    In March of last year, the league finally loosened the rules around players consuming cannabis in its labour agreement, and players can no longer be suspended if they test positive. 

    Players join the green rush

    A long list of former NFL players have entered the cannabis space post-retirement, like Tiki Barber, Rob Gronkowski, Eugene Monroe and even Joe Montana. Former running back Ricky Williams estimates he lost between $5 and $10 million during his career because of failed drug tests and lost endorsements due to unapologetic cannabis use. Now he’s the founder of Real Wellness Herbal, a medical cannabis company.

    “The story was ‘football player retires to go smoke pot,’” he told CNBC. “And, part of that was true, but it was much bigger than that . I was really redefining myself and figuring out what I want to do with my life.”

    BofC

    Share Article

    The Briefing / Newsletter

    Insights
    you don't want
    to miss.

    A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.

    • Policy & regulation
    • Markets & deals
    • Clinical & science
    Subscribe free